Kenworthy KE, Bloomer JC, Clarke SE, Houston JB. CYP3A4 drug interactions:
correlation of 10in vitroprobe substrates. Br J Clin Pharmacol 1999;48:716–
727.
Kitz R, Wilson IB. Esters of methanesulfonic acid as irreversible inhibitors of
acetylcholinesterase. J Biol Chem 1962;237:3245–3249.
Kremers P.In vitrotests for predicting drug–drug interactions: the need for validated
procedures. Pharmacol Toxicol 2002;91:209–217.
Lai AA, Levy RH, Cutler RE. Time-course of interaction between carbamazepine and
clonazepam in normal man. Clin Pharmacol Ther 1978;24:316–323.
Lin JH. Sense and nonsense in the prediction of drug–drug interactions. Curr Drug
Metab 2000;1:305–331.
Lin JH, Lu AY. Interindividual variability in inhibition and induction of cytochrome
P450 enzymes. Annu Rev Pharmacol Toxicol 2001;41:535–567.
Lu P, Schrag ML, Slaughter DE, Raab CE, Shou M, Rodrigues AD. Mechanism-
based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a
5-lipoxygenase inhibitor. Drug Metab Dispos 2003;31:1352–1360.
Luo G, Lin J, Fiske WD, Dai R, Yang TJ, Kim S, Sinz M, LeCluyse E, Solon E,
Brennan JM, Benedek IH, Jolley S, Gilbert D, Wang L, Lee FW, Gan LS.
Concurrent induction and mechanism-based inactivation of CYP3A4 by an
L-valinamide derivative. Drug Metab Dispos 2003;31:1170–1175.
Mayhew BS, Jones DR, Hall SD. Anin vitromodel for predictingin vivoinhibition of
cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab
Dispos 2000;28:1031–1037.
Moody GC, Griffin SJ, Mather AN, McGinnity DF, Riley RJ. Fully automated
analysis of activities catalysed by the major human liver cytochrome P450 (CYP)
enzymes: assessment of human CYP inhibition potential. Xenobiotica 1999;29:
53–75.
Nomeir AA, Ruegg C, Shoemaker M, Favreau LV, Palamanda JR, Silber P, Lin CC.
Inhibition of CYP3A4 in a rapid microtiter plate assay using recombinant enzyme
and in human liver microsomes using conventional substrates. Drug Metab Dispos
2001;29:748–753.
Obach RS. Drug–drug interactions: an important negative attribute in drugs. Drugs
Today (Barc) 2003;39:301–338.
Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, Tremaine LM.
The utility ofin vitrocytochrome p450 inhibition data in the prediction of drug–drug
interactions. J Pharmacol Exp Ther 2006;316:336–348.
Obach RS, Walsky RL, Venkatakrishnan K, Houston JB, Tremaine LM.In vitro
cytochrome P450 inhibition data and the prediction of drug–drug interactions:
qualitative relationships, quantitative predictions, and the rank-order approach. Clin
Pharmacol Ther 2005;78:582–592.
Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients
receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol
Ther 1994;55:481–485.
Pessayre D, Larrey D, Vitaux J, Breil P, Belghiti J, Benhamou JP. Formation of an
inactive cytochrome P-450 Fe(II)-metabolite complex after administration of
troleandomycin in humans. Biochem Pharmacol 1982;31:1699–1704.
542 ANALYSIS OFIN VITROCYTOCHROME P450 INHIBITION